Calixar and Synthelis team up to provide unique membrane protein services
Calixar and Synthelis announced that they have entered into an alliance for the production and isolation of all types of target membrane proteins. The results of this collaboration will have applications ranging from the development of antibodies to the discovery of new drugs, including the determination of the structure of these targets and vaccine formulations.
Instead of trying to produce these proteins themselves, users will be given access to state-of-the-art production and purification technologies, enabling them to concentrate on their core activities. Furthermore, thanks to the critical mass of skills and technologies made available to them, they will be assured of obtaining targets in their native conformation, thus guaranteeing the success of their programs for developing new drugs, vaccines and therapeutic antibodies.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous